Figure 2
HD daunorubicin is necessary for benefit of the NPM1 mutation. Data for overall survival from the intention-to-treat analysis are shown for patients with NPM1 mutant and NPM1 wild-type AML by receipt of HD daunorubicin or SD daunorubicin.
HD daunorubicin is necessary for benefit of the NPM1 mutation. Data for overall survival from the intention-to-treat analysis are shown for patients with NPM1 mutant and NPM1 wild-type AML by receipt of HD daunorubicin or SD daunorubicin.
